Sight Sciences Third Quarter 2026 Earnings Results - SIGHT SCIENCES INC

Financial Performance:

• Q3 2026 revenue reached a record $24.9 million, representing 25% year-over-year growth; this marks the third consecutive quarter of double-digit growth and the second of 20%+ growth.
• Net loss narrowed to $6.8 million ($0.12 per share), a 17% improvement from $8.2 million ($0.16 per share) in the prior year period.
• Gross margin stood at 86%; IG margin was 87%, while IDE margin significantly improved to 79% from 38% YoY, driven by higher average selling prices.
• Cash usage improved dramatically by 74% sequentially to $2.4 million and by 48% year-to-date to $14.6 million, despite continued investment in growth.
• Company ended the quarter with $77.4 million in cash and cash equivalents and $40 million in debt (excluding unamortized discounts); debt interest-only period extended to August 2027.
• Year-to-date revenue grew 19% while adjusted operating expenses declined 2%, demonstrating operating leverage.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $92–$93 million (up from $88–$92 million), driven by revised IDE and IG forecasts.
• New 2026 segment guidance: IDE revenue projected at approximately $12 million (up from $9–$11 million); IG revenue projected at $80–$81 million (up from $79–$81 million).
• Maintained adjusted operating expense guidance for 2026 at $92–$94 million, implying 5–7% full-year growth.
• Management anticipates entering 2027 with significant momentum, expecting sustained revenue growth in both IG and accelerating contribution from IDE as market access expands.
• Full-year 2026 revenue growth is expected to average approximately 20% at the midpoint.

Business Segments and Product Lines:

• Interventional Glaucoma (IG): Generated $21 million in Q3 (7% YoY growth), driven by higher volumes and a record number of active accounts.
• Interventional Dry Eye (IDE): Generated a record $3.9 million in Q3 (45% sequential growth); ordering accounts rose to 222 (from 176) with utilization increasing to 21 SmartLids per account (from 18).
• OmniUltra Launch: Commercially launched the next-generation OmniUltra product in October, featuring single-pass canaloplasty, TrueSync Plus, and improved catheter visualization.
• TierCare FDA Expansion: Received FDA label expansion to become the first and only treatment indicated to improve meibomian gland function (MGD) in dry eye disease patients.
• Strategic Focus (IX): Highlighted the "Intersection of Intervention" (IX), leveraging synergies where glaucoma and dry eye treatments overlap in patient care pathways and practice workflows.

Market and Competitive Landscape:

• Positioning as the pioneer in interventional eye care categories for glaucoma and dry eye, with over 500,000 procedures performed using their technologies.
• IDE adoption is accelerating in reimbursed markets, specifically focusing on practices with high volumes of traditional Medicare patients to establish fee schedules.
• Market share gains in IG driven by active account growth and the "combo cataract" trend, where glaucoma intervention is performed alongside cataract surgery.
• Payer engagement is ongoing with MACs and commercial payers to establish fee schedules for TierCare, leveraging the new FDA label and clinical data.
• The standalone interventional glaucoma market remains an under-penetrated opportunity; the company is activating standalone workflows to move beyond physician education to practical adoption.

Risks and Challenges:

• IDE growth is currently constrained by limited market access and reimbursement coverage in only specific regions (e.g., First Coast, Novitas); scaling depends on broader payer approval.
• Standalone IG adoption requires significant effort to shift clinical workflows and convince practices to treat patients separately from cataract procedures.
• Payer coverage policy timelines are uncertain; while confidence is high regarding future fee schedules, exact timing for expanded access cannot be predicted.
• The business remains in a growth investment phase, with adjusted OpEx expected to grow 5–7% to support the scaling of IDE and commercial operations.

Management Commentary and Tone:

• Tone was highly confident and positive, emphasizing "record revenue," "operating leverage," and "strong momentum."
• Management expressed pride in achieving growth while simultaneously significantly reducing cash burn.
• Leadership reiterated the strategic value of their two-pronged interventional approach, citing the "durable" nature of the business model as market access expands.
• CEO Paul Badawi highlighted the clinical narrative of treating the "underlying cause of disease" as a key differentiator in sales messaging.

Analyst Questions and Answers:

• Q (Lake Street): Asked about the implied Q4 growth deceleration in guidance. A (Jim Rodberg): Guidance includes conservatism to account for market development stages and seasonality; Q4 momentum is expected to continue into 2027.
• Q (Lake Street): Inquired about IDE utilization potential. A (Allie Bauerlein): Utilization is early-stage; current average is 21, but high-volume accounts show higher rates. Growth potential exists as market access expands to commercial payers.
• Q (Stifel): Asked about 2027 confidence and IG growth rates. A (Management): Confident in 2027 growth driven by Ultra launch and IG fundamentals; IG expected to maintain low-to-mid single-digit CAGR, while IDE accelerates.
• Q (Stifel): Asked about the impact of the TierCare label expansion on payers. A (Paul Badawi/Allie Bauerlein): Label validates treating the underlying cause (MGD), which is a strong lever for payer education and coverage discussions; field reaction has been positive.
• Q (William Blair): Asked about future OPEX trends. A (Jim Rodberg): Committed to targeted investments behind high-growth opportunities (IDE scaling), maintaining a strategy where revenue growth outpaces expense growth to reach cash flow break-even.
• Q (Piper Sandler): Asked about the IDE guidance implication of Q4 sequential decel. A (Management): Conservative guidance reflects early-stage market dynamics; focus remains on durable account growth and eventual scaling.
• Q (Citi): Asked about accelerating the standalone IG market. A (Paul Badawi): Focus is on "activation" workflows, training practices to identify appropriate patients for standalone procedures similar to cataract workflows, moving beyond clinical education.
• Q (Needham): Asked about IX synergy and pre-op dry eye treatment. A (Management): Seeing high-volume cataract surgeons adopting TierCare to treat dry eye before cataract surgery, leveraging the overlap in patient conditions.
• Q (HC Wainwright): Asked about debt amortization extension. A (Jim Rodberg): Extension to August 2027 provides optionality and liquidity for growth investments; company is managing toward cash flow break-even.

Other Key Points:

• OmniUltra launch at the American Academy of Ophthalmology (AAO) annual meeting in New Orleans was a key event, with early user feedback citing versatility and ease of use.
• The company is actively engaging with MACs (Medicare Administrative Contractors) and commercial payers to establish fee schedules, citing increasing claims data as a catalyst for policy decisions.
• The "IX" strategy is described as a proprietary differentiator, creating a scalable platform that leverages shared customers and overlapping patient conditions across glaucoma and dry eye care.
• Management remains focused on fiscal discipline, ensuring that investments in IDE commercial resources and market access do not derail the path to cash flow break-even.